TABLE 1.
Characteristics of patients (n = 76) with MDR-TB who were initiating treatment with linezolid-containing regimensa
| Characteristic | Value |
|---|---|
| Age (median [IQR] [yrs]) | 36.8 (27.7–49.9) |
| Body mass index (median [IQR] [kg/m2]) | 19.9 (18.4–22.4) |
| No. (%) male | 59 (77.6) |
| Any tobacco usee (no. [%]) | 37 (48.7) |
| More than 1 pack per day | 19 (25.0) |
| Any alcohol usee (no. [%]) | 23 (30.3) |
| Heavyb | 8 (10.5) |
| Diabetes mellitus (no. [%]) | 10 (13.2) |
| HIV infection (no. [%]) | 2 (2.6) |
| Hepatitis C antibody positive (no. [%]) | 19 (25.0) |
| Case definitions (no. [%]) | |
| New | 34 (44.7) |
| Relapse | 15 (19.7) |
| After loss to follow-up | 10 (13.2) |
| After failure | 10 (13.2) |
| Other | 7 (9.2) |
| Pulmonary disease only (no. [%]) | 75 (98.7) |
| Cavitary disease (no. [%]) | 47 (61.8) |
| AFB sputum smear positivec (no. [%]) | 54 (71.1) |
| Extensive drug resistance (no. [%]) | 16 (21.1) |
| Baseline laboratory values (median [IQR]) | |
| White blood cells (×103/μL) | 9.4 (7.5–11.0) |
| Hemoglobin (g/dL) | 12.5 (11.3–14.0) |
| Platelets (×103/μL) | 373 (306–488.5) |
| Creatinine (μmol/L) | 71 (61–84) |
| Treatment characteristics (median [IQR]) | |
| SLD treatment duration (days) | 609 (461–622) |
| New drugd treatment duration (days) | 532 (348–608) |
| Linezolid duration (days) | 526 (305–607) |
| Treatment duration prior to linezolid start (days) | 27.5 (0–112) |
| Linezolid stop prior to completion (no. [%]) | |
| Adverse event | 4 (5.3) |
| Poor outcome | 13 (17.1) |
| Clinical outcomes (no. [%]) | |
| Favorable outcome | 53 (69.7) |
| Any acquired drug resistance | 12 (16.2) |
a
MDR-TB, multidrug-resistant TB; TB, tuberculosis; PK, pharmacokinetic; IQR, interquartile range; HIV, human immunodeficiency virus; SLD, second-line drugs.
b
“Heavy” represents >15 drinks per week for men and >8 drinks per week for women.
c
At time of new drug initiation.
d
New anti-TB drugs include bedaquiline, linezolid, clofazimine, and delamanid.
e
Reported within 12 weeks of diagnosis.